CART cells are prone to Fas- and DR5-mediated cell death

Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies

(2017) Maria Caterina Rotiroti et al.   HUMAN GENE THERAPY

CAR T-cell therapy of solid tumors

(2017) Carmen S M Yong et al.   IMMUNOLOGY AND CELL BIOLOGY

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

(2017) Jun Liu et al.   Journal of Hematology & Oncology

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

(2017) Arnab Ghosh et al.   LEUKEMIA & LYMPHOMA

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity

(2017) Arnab Ghosh et al.   NATURE MEDICINE

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

(2017) Yinmeng Yang et al.   Science Translational Medicine

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

(2017) Diogo Gomes-Silva et al.   Cell Reports

Driving gene-engineered T cell immunotherapy of cancer

(2016) Laura A Johnson et al.   CELL RESEARCH

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Production of retroviral constructs for effective transfer and expression of T-cell receptor genes using Golden Gate cloning

(2015) Lori V. Coren et al.   BIOTECHNIQUES

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

(2015) A. Morello et al.   Cancer Discovery

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice

(2013) D. Chinnasamy et al.   CANCER RESEARCH

CD3ζ-based chimeric antigen receptors mediate T cell activation viacis- andtrans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

(2013) J. S. Bridgeman et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Complete but curtailed T-cell response to very low-affinity antigen

(2009) Dietmar Zehn et al.   NATURE

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE